Journal for ImmunoTherapy of Cancer (Apr 2022)
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
- Matthew King,
- Melissa Chapman,
- Vasu Sah,
- Paul Lyne,
- Alexey Revenko,
- Charles Sinclair,
- Ben Johnson,
- Maneesh Singh,
- Andrew Watt,
- Maelle Mairesse,
- Larissa S Carnevalli,
- Alison Peter,
- Molly Taylor,
- Lisa Hettrick,
- Stephanie Klein,
- Anisha Solanki,
- Danielle Gattis,
- Adina M Hughes,
- Lukasz Magiera,
- Gozde Kar,
- Lucy Ireland,
- Deanna A Mele,
- Josephine Walton,
- Mark Edbrooke,
- Simon T Barry,
- Stephen Fawell,
- Frederick W Goldberg,
- A Robert MacLeod
Affiliations
- Matthew King
- La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Victoria, Australia
- Melissa Chapman
- NPS MedicinWise, Sydney, Australia
- Vasu Sah
- Aff3 grid.418152.bAstraZeneca Ltd 35 Gatehouse Lane Waltham USA
- Paul Lyne
- Aff2 grid.418152.bOncology, IMED Biotech UnitAstraZeneca Pharmaceuticals Waltham MA USA
- Alexey Revenko
- Aff4 0000 0004 0386 1252grid.282569.2Department of Antisense Drug DiscoveryIonis Pharmaceuticals, Inc. Carlsbad CA USA
- Charles Sinclair
- Aff1 Bioscience, Oncology, IMED Biotech Unit AstraZeneca Francis Crick Ave CB2 0SL Cambridge UK
- Ben Johnson
- University Hospitals Birmingham, Birmingham, UK
- Maneesh Singh
- Gold Coast and Robina Hospitals, Brisbane, Australia.
- Andrew Watt
- Ionis Pharmaceuticals, Carlsbad, California, USA
- Maelle Mairesse
- 1ImCheck Therapeutics, Marseille, France
- Larissa S Carnevalli
- Oncology R&D, AstraZeneca, Cambridge, UK
- Alison Peter
- Oncology R&D, AstraZeneca, Cambridge, UK
- Molly Taylor
- Oncology R&D, AstraZeneca, Cambridge, UK
- Lisa Hettrick
- Ionis Pharmaceuticals, Carlsbad, California, USA
- Stephanie Klein
- Ionis Pharmaceuticals, Carlsbad, California, USA
- Anisha Solanki
- Oncology R&D, AstraZeneca, Cambridge, UK
- Danielle Gattis
- Ionis Pharmaceuticals, Carlsbad, California, USA
- Adina M Hughes
- Oncology R&D, AstraZeneca, Cambridge, UK
- Lukasz Magiera
- Oncology R&D, AstraZeneca, Cambridge, UK
- Gozde Kar
- Oncology R&D, AstraZeneca, Cambridge, UK
- Lucy Ireland
- Oncology R&D, AstraZeneca, Cambridge, UK
- Deanna A Mele
- Oncology R&D, AstraZeneca, Waltham, MA, USA
- Josephine Walton
- Oncology R&D, AstraZeneca, Cambridge, UK
- Mark Edbrooke
- Oncology R&D, AstraZeneca, Cambridge, UK
- Simon T Barry
- Oncology R&D, AstraZeneca, Cambridge, UK
- Stephen Fawell
- Oncology R&D, AstraZeneca, Waltham, MA, USA
- Frederick W Goldberg
- Oncology R&D, AstraZeneca, Cambridge, UK
- A Robert MacLeod
- Ionis Pharmaceuticals, Carlsbad, California, USA
- DOI
- https://doi.org/10.1136/jitc-2021-003892
- Journal volume & issue
-
Vol. 10,
no. 4
Abstract
No abstracts available.
